I
Ivan Capobianco
Researcher at University of Tübingen
Publications - 24
Citations - 579
Ivan Capobianco is an academic researcher from University of Tübingen. The author has contributed to research in topics: Hepatectomy & Liver transplantation. The author has an hindex of 9, co-authored 19 publications receiving 406 citations. Previous affiliations of Ivan Capobianco include University of Montpellier.
Papers
More filters
Journal ArticleDOI
Indications and Limits for Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS). Lessons Learned from 15 Cases at a Single Centre
Silvio Nadalin,Ivan Capobianco,Jun Li,Paolo N. C. Girotti,Ingmar Königsrainer,Alfred Königsrainer +5 more
TL;DR: The actual high morbidity and mortality rates related to the ALPPS procedure should lead to a more cautious selection of the candidates for this operation and restriction of the indications through an accurate work-up based on interdisciplinary cooperation among hepatologists, oncologists, radiologists and surgeons.
Journal ArticleDOI
Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity.
Michael Linecker,Bergthor Björnsson,Gregor A. Stavrou,Karl J. Oldhafer,Georg Lurje,Ulf P. Neumann,René Adam,François-René Pruvot,Stefan A. Topp,Jun Li,Ivan Capobianco,Silvio Nadalin,Marcel Autran C. Machado,Sergey Voskanyan,Deniz Balci,Roberto Hernandez-Alejandro,Roberto Hernandez-Alejandro,Fernando A. Alvarez,Eduardo de Santibañes,Ricardo Robles-Campos,Massimo Malagó,Michelle L. de Oliveira,Mickael Lesurtel,Pierre-Alain Clavien,Henrik Petrowsky +24 more
TL;DR: Risk adjustment of patient selection and technique in ALPPS resulted in a continuous drop of early mortality and major postoperative morbidity, which has meanwhile reached standard outcome measures accepted for major liver surgery.
Journal ArticleDOI
The ALPPS Risk Score: Avoiding Futile Use of ALPPS.
Michael Linecker,Gregor A. Stavrou,Karl J. Oldhafer,Robert M. Jenner,Burkhardt Seifert,Georg Lurje,Jan Bednarsch,Ulf P. Neumann,Ivan Capobianco,Silvio Nadalin,Ricardo Robles-Campos,Eduardo de Santibañes,Massimo Malagó,Mickael Lesurtel,Pierre-Alain Clavien,Henrik Petrowsky +15 more
TL;DR: Both models have an excellent prediction to assess the individual risk of futile outcome after ALPPS surgery and can be used to avoid futile use of ALPPS.
Journal ArticleDOI
Paradigm Shift in the Management of Irresectable Colorectal Liver Metastases: Living Donor Auxiliary Partial Orthotopic Liver Transplantation in Combination With Two-stage Hepatectomy (LD-RAPID).
Alfred Königsrainer,Silke Templin,Ivan Capobianco,Ingmar Königsrainer,Michael Bitzer,Lars Zender,Bence Sipos,Lothar Kanz,Silvia Wagner,Silvio Nadalin +9 more
TL;DR: The first case of resection and partial liver segment 2-3 transplantation with delayed total hepatectomy (RAPID) from living donor in a patient affected of irresectable colorectal liver metastases (i-CRLM) is reported.
Journal ArticleDOI
First Long-term Oncologic Results of the ALPPS Procedure in a Large Cohort of Patients With Colorectal Liver Metastases.
Henrik Petrowsky,Michael Linecker,Dimitri A. Raptis,Christoph Kuemmerli,Ralph Fritsch,Onur Elvan Kirimker,Deniz Balci,Francesca Ratti,Luca Aldrighetti,Sergey Voskanyan,Federico Tomassini,Roberto Troisi,Jan Bednarsch,Georg Lurje,Georg Lurje,Mohammad-Hossein Fard-Aghaie,Tim Reese,Karl J. Oldhafer,Omid Ghamarnejad,Arianeb Mehrabi,Mauro E Tun Abraham,Stéphanie Truant,François-René Pruvot,Emir Hoti,Patryk Kambakamba,Ivan Capobianco,Silvio Nadalin,Eduardo Fernandes,Philipp Kron,Philipp Kron,Peter Lodge,Pim B. Olthof,Thomas M. van Gulik,Carlos Castro-Benitez,René Adam,Marcel Autran C. Machado,Martin Teutsch,Jun Li,Marcus N. Scherer,Hans J. Schlitt,Victoria Ardiles,Eduardo de Santibañes,Roberto Brusadin,Victor Lopez-Lopez,Ricardo Robles-Campos,Massimo Malagó,Roberto Hernandez-Alejandro,Roberto Hernandez-Alejandro,Pierre-Alain Clavien +48 more
TL;DR: This large cohort provides the first evidence that patients with primarily unresectable CRLM treated by ALPPS have not only low perioperative mortality, but achieve appealing long-term oncologic outcome especially those with favorable tumor biology and good response to chemotherapy.